Industry Standard

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Retrieved on: 
星期二, 三月 12, 2024
Patient, SAN, Industry Standard, Compatibility, ISR, Overalls, Corporate title, Big Pharma, Fine chemical

The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.

Key Points: 
  • The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.
  • Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey.
  • Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.
  • With each investment in technology, quality, and facilities, we elevate our capabilities, ensuring we meet and exceed our client's needs.

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Retrieved on: 
星期二, 三月 12, 2024
Patient, SAN, Industry Standard, Compatibility, ISR, Overalls, Corporate title, Big Pharma, Fine chemical

The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.

Key Points: 
  • The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.
  • Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey.
  • Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.
  • With each investment in technology, quality, and facilities, we elevate our capabilities, ensuring we meet and exceed our client's needs.

Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

Retrieved on: 
星期五, 二月 16, 2024
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, ISR, Thermo Fisher Scientific, Patient, Benchmarking, Organization, Industry Standard

For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.

Key Points: 
  • For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.
  • In total, customers evaluated 98 companies across 23 performance metrics for these honors, which distinguish the top contract manufacturing organizations by surveying leading global pharma and biotech companies.
  • That research, based on the Contract Manufacturing Quality Benchmarking conducted by Industry Standard Research (ISR), involved customers of all sizes that worked with the contract manufacturers during the prior 18 months.
  • Those best at serving their customers (and thus patients) are recognized as the 2024 CDMO Leadership Award winners.

Curia Receives 2024 CDMO Leadership Award

Retrieved on: 
星期一, 二月 5, 2024
Service, Industry Standard, Conference, Fine chemical

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group.

Key Points: 
  • ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group.
  • “Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia.
  • “Congratulations to our 2024 CDMO Leadership Award winners.
  • The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”

Worldwide Clinical Trials Completes Recapitalization with Kohlberg & Company

Retrieved on: 
星期二, 十二月 12, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Compatibility, Research, Investment, Patient, ISR, Culture, TJC, Late Phases, Worldwide, Partnership, Industry Standard, Clinical trial, Growth, Medicine, Kohlberg & Company, Management, Fine chemical, Pharmaceutical industry, Kohlberg

Worldwide Clinical Trials (“Worldwide”), a privately held, leading global, full-service contract research organization (“CRO”), has announced the closing of its previously announced recapitalization that gives funds managed by Kohlberg & Company, LLC (“Kohlberg”), a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, a majority stake in the company.

Key Points: 
  • Worldwide Clinical Trials (“Worldwide”), a privately held, leading global, full-service contract research organization (“CRO”), has announced the closing of its previously announced recapitalization that gives funds managed by Kohlberg & Company, LLC (“Kohlberg”), a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, a majority stake in the company.
  • “This is a significant milestone for Worldwide – one that positions us for further growth and expands our ability to deliver best in class partnerships for our customers while cultivating a culture for our team members to do their best, mission-oriented work,” said Peter Benton , President and CEO, Worldwide Clinical Trials.
  • This investment by Kohlberg, and continued investment by TJC, elevates our approach to best support our customers and continue delivering customized clinical research programs.”
    With this transaction, Matt Jennings , Operating Partner of Kohlberg, becomes Chairman of Worldwide’s Board of Directors.
  • Worldwide remains a privately held company with no other changes to its leadership team, employee base, or customer experience.

Medidata and EDETEK Announce Partnership to Revolutionize Global Clinical Trial Data Management

Retrieved on: 
星期二, 十一月 7, 2023
EDC, Medidata Solutions, Informatics, Life, Data science, Clinical trial, Partnership, Patient, Dassault Group, Industry Standard, Medical imaging, Fine chemical, Pharmaceutical industry

PRINCETON, N.J., Nov. 7, 2023 /PRNewswire/ -- Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and EDETEK , an industry trailblazer in digital clinical solutions and services, announced an enterprise-level partnership set to transform study conduct and clinical data management.

Key Points: 
  • PRINCETON, N.J., Nov. 7, 2023 /PRNewswire/ -- Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and EDETEK , an industry trailblazer in digital clinical solutions and services, announced an enterprise-level partnership set to transform study conduct and clinical data management.
  • The strategic partnership aims to provide integrated, end-to-end solutions for biopharmaceutical, medical devices companies, and clinical research organizations in the global biopharmaceutical industry.
  • Elevated Technical Expertise: Partnership combines EDETEK's experience in clinical informatics with Medidata's deep technical knowledge delivering domain and industry-focused expertise to customers.
  • "EDETEK's alliance with Medidata underscores our shared vision to enhance clinical research efficiency and efficacy," said Jian Chen, President, EDETEK.

Amartus and ServiceNow Partner to Offer Industry Standard Inter-Party Automation Process and APIs

Retrieved on: 
星期二, 五月 16, 2023
Networks, Data Management, Technology, Telecommunications, Software, Partnership, Network, Intranet, Business process network, API, Service, Automation, Industry Standard, MEF, Management control system, Hewlett Packard Enterprise Networking, Comparison of issue-tracking systems, ServiceNow, Enterprise, Asset management, Amartus

Amartus, a leading provider of Industry Standard Inter-party Automation software, has partnered with ServiceNow to offer Enterprises and Service Providers a combined solution for rapid implementation of MEF LSO (Life-cycle Service Orchestration) industry standard processes and APIs to automate trading & operation of services that underpin todays Enterprise Network & IT environments.

Key Points: 
  • Amartus, a leading provider of Industry Standard Inter-party Automation software, has partnered with ServiceNow to offer Enterprises and Service Providers a combined solution for rapid implementation of MEF LSO (Life-cycle Service Orchestration) industry standard processes and APIs to automate trading & operation of services that underpin todays Enterprise Network & IT environments.
  • No single service provider offers the range and reach of services involved; they must partner with others.
  • “Amartus nBrace™ Inter-provider Automation perfectly complements ServiceNow, by enabling plug-n-play, API driven inter-operability between service providers as well as between enterprises and service providers.
  • “By working in partnership with ServiceNow, we make it easier for Enterprises and Service Providers to implement the standards.

Transphorm Introduces Six SuperGaN FETs Pin-to-Pin Compatible With e-mode Devices

Retrieved on: 
星期四, 四月 27, 2023
Semiconductor, Hardware, Manufacturing, Technology, Engineering, Business development, Senior, BOM, Data-rate units, SIP, Temperature, Industry Standard, Marketing, TCR, FET (timetabling software), Gallium nitride, Printed circuit board, Transformer, Transphorm

These SMDs deliver the reliability and performance advantages offered by Transphorm’s patented SuperGaN® d-mode two-switch normally-off platform in the package configurations typically used by competitive e-mode GaN devices.

Key Points: 
  • These SMDs deliver the reliability and performance advantages offered by Transphorm’s patented SuperGaN® d-mode two-switch normally-off platform in the package configurations typically used by competitive e-mode GaN devices.
  • For power systems that require additional thermal performance from the SuperGaN platform, Transphorm also offers SMDs in optimized Performance packages.
  • All Transphorm devices offer easy designability and drivability regardless of packaging given the d-mode configuration’s use of a low-voltage Silicon MOSFET paired with the GaN HEMT.
  • In the charger analysis, the SuperGaN FETs operated at the controller’s output voltage range (whereas e-mode had to level shift) with cooler temperatures.

Transphorm at PCIM 2023: Superior GaN Solutions Powering Electric Vehicle Systems to Adapters

Retrieved on: 
星期三, 四月 19, 2023
Semiconductor, Engineering, Automotive Manufacturing, Technology, Manufacturing, Hardware, EPI, Renewable resource, PD, FIT, SIP, APEC, Design for manufacturability, Industry Standard, Hall, TSMC, DSC, AEC, Silicon, FET, Gallium nitride, Video game, Transphorm, Designability

Devices on display will demonstrate Transphorm’s ability to support low to high power systems with GaN power conversion solutions offering unparalleled Manufacturability, Designability, Drivability, and Reliability.

Key Points: 
  • Devices on display will demonstrate Transphorm’s ability to support low to high power systems with GaN power conversion solutions offering unparalleled Manufacturability, Designability, Drivability, and Reliability.
  • And, at PCIM, Transphorm will again achieve a critical milestone by unveiling design resources for the 1200 V GaN device first demonstrated a year ago .
  • This device will complement the company’s already strong 650 V solutions enabling various electric vehicle applications.
  • Learn more about how Transphorm’s GaN platform impacts power systems across all power levels during the Bodo’s Power Systems session.

EQS-News: Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status

Retrieved on: 
星期一, 三月 20, 2023
Business development, Partnership, Senior, ISR, Rentschler, Research, Industry Standard, Compatibility, CDMO, Publication, Patient, Conference, Republican Conference Chair, Fine chemical

Champion status in the Compatibility category highlights outstanding cultural fit, project management and reputation

Key Points: 
  • Champion status in the Compatibility category highlights outstanding cultural fit, project management and reputation
    Laupheim, Germany, March 20, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is proud to announce that the company has been awarded CDMO Leadership Awards in the categories of Service, Reliability, Capabilities and Compatibility.
  • In addition, Rentschler was recognized as a CDMO Leadership Award Champion in the Compatibility category.
  • The awards are based on client feedback and honor Rentschler’s overall service performance for big and small pharma combined.
  • The CDMO Leadership Awards Ceremony and Reception will be held in New York City on March 22, 2023.